70.21
-1.64%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Gan & Lee Pharmaceuticals
Its shares trade on Shanghai under the ticker 603087.SS. It has been listed since 29 June 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥4.05bn and net income of CN¥1.14bn. At that date it held total assets of CN¥12.63bn and shareholders' equity of CN¥11.63bn.
Gan & Lee Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of recombinant insulin analogue raw materials and injections. The company is headquartered in Beijing, Beijing. The company went IPO on 2020-06-29. The firm's main products include insulin glargine injection Changxiulin, insulin lispro injection Suxiulin, protamine zinc recombinant insulin lispro mixed injection (25R) Suxiulin 25, Insulin Aspart Injection Ruixilin, Insulin Aspart 30 Injection Ruixilin30, Protamine Human Insulin Mixed Injection (30R) Puxilin30 and many other insulin analogs and human insulin varieties, covering three functional market segments of long-acting, rapid-acting and premixed insulin.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Jun 2020
- Employees
- 4,057
- Website
- ganlee.com.cn ↗
Leadership
Pay as last reported
- Mr. Zhongru GanChairman of the Board, since 1998CN¥457,200
- Mr. Cheng SunFinance Director, Deputy General ManagerCN¥695,200
- Mr. Kai DuGeneral Manager, Director, since 2016CN¥1.0m
- Mr. Wei ChenDeputy General Manager, Director, since 2021CN¥892,200
- Mr. Weiqiang SongDeputy General Manager, Director, since 2015CN¥960,500
- Mr. Zhi LiDeputy General Manager
- Ms. Cheng XingDeputy General ManagerCN¥752,800
- Ms. Zifei YuanDeputy General ManagerCN¥710,500
- Ms. Rong ZouSecretary of the BoardCN¥695,000
- Ms. Jiao JiaoDirectorCN¥1.0m
- Mr. Lei YinDirectorCN¥897,100
- Mr. Zengyi ChangIndependent DirectorCN¥72,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 46
- Environment
- 33
- Social
- 45
- Governance
- 60
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Gan & Lee Pharmaceuticals develops insulin glargine injection Changxiulin for long-acting insulin needs.
- The company produces insulin lispro injection Suxiulin for rapid-acting insulin applications.
- Gan & Lee Pharmaceuticals offers protamine zinc recombinant insulin lispro mixed injection Suxiulin 25 for premixed insulin segments.
Weaknesses
- Gan & Lee Pharmaceuticals has only one headquarters city, Beijing, for its operations.
- The company's business is limited to insulin analogs and human insulin varieties only.
- Gan & Lee Pharmaceuticals has no mention of international market presence beyond China.
Opportunities
- Gan & Lee Pharmaceuticals can expand into the growing global insulin market segments.
- The company may leverage its product portfolio for new market segments in China.
- Gan & Lee Pharmaceuticals can target the increasing demand for insulin analogs in Asia.
Threats
- Gan & Lee Pharmaceuticals faces competition from other insulin producers in China.
- The company's reliance on insulin analogs may be threatened by new medical treatments.
- Gan & Lee Pharmaceuticals could be affected by regulatory changes in the Chinese healthcare sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.